Who's Responsible for Cannabis Safety in Switzerland?

Ask for a lab report at a Swiss street dealer and you will get a blank look. Ask at one of the pharmacies in Zürich, Basel, Bern, Biel or Lucerne that take part in a federal pilot trial and the answer is printed on a sealed, plain pack. Switzerland now runs four cannabis systems side by side. Here is who is responsible for each, and how to tell which one you are buying from.

Four systems, one small country

The illegal market. Growing, importing, producing and selling cannabis with 1 percent THC or more is banned under the Narcotics Act. Using it is a minor offence: an adult caught consuming pays a fixed CHF 100 fine, and up to 10 grams counts as a minor quantity. Nobody tests this cannabis, and it is what most of Switzerland's roughly 220,000 monthly users buy.

CBD and low-THC hemp. Anything under 1 percent THC falls outside the Narcotics Act. It is policed product by product as a food, cosmetic, tobacco product, chemical or medicine, mostly through the seller's own self-monitoring, with the cantonal chemists and Swissmedic behind them. No health claims are allowed. Since October 2024, CBD flower and CBD e-liquids may be sold as smoking products under the tobacco products law, with its warnings.

Medical cannabis. Since 1 August 2022 doctors can prescribe cannabis on a narcotics prescription without asking the federal health office for an exemption. Cultivation, processing and trade sit under Swissmedic's licensing and control system, and most products are magistral preparations, mostly oils and tinctures, made under GMP by the pharmacy or a specialised manufacturer from flowers that meet the European Pharmacopoeia cannabis monograph. Only one finished product, Sativex, is authorised. Health insurers pay only exceptionally, and patients typically spend CHF 300 to 500 a month.

The pilot trials. Since 15 May 2021 an article in the Narcotics Act lets public or private organisations, from cities and universities to associations and companies, run scientific trials of regulated sale, until 2031 at the latest. The Federal Office of Public Health (FOPH) has authorised eight of them, from Basel's Weed Care to the newest, CanLeg in the canton of St. Gallen, which is the first to test home delivery. About 10,400 adults were enrolled across the seven trials then running by June 2025, roughly a thousand of them in a Zürich control group that still buys on the black market.

Who checks that it is safe

Inside a trial the responsibility is split across four layers:

Licensed producers grow the cannabis in Switzerland, organically and to good agricultural and collection practice, are responsible for each batch's total THC, CBD and contaminant results, and keep a 250-gram retention sample of every batch for three years.

Certified analytical laboratories run those analyses, potency and contaminants alike, by recognised methods.

The cantons designate the control bodies that check product quality and can pull that retention sample at any time; communes approve each sales point; a cantonal ethics committee approves the study itself.

The FOPH authorises every trial after hearing the canton and commune, funds the track-and-trace system, inspects, receives annual reports and any extraordinary event immediately, and can withdraw a licence.

Independent researchers evaluate the whole programme for the FOPH. Their second interim report, published in January 2026, recorded no notable incidents in any trial.

What "tested" actually means

The pilot trials ordinance sets the bar. Every product must be free of health-relevant foreign matter, microbial contaminants, mycotoxins, heavy metals, pesticides and solvent residues, within limits listed in its annex. Total THC may not exceed 20 percent, and an edible or drinkable unit may carry at most 10 milligrams. The potency printed on the pack may deviate from the lab result by up to 25 percent for unprocessed flower and 15 percent for processed products, so a "16 percent" pack can legally contain 12 to 20. No additives that raise the psychoactive effect or the toxicity are allowed, and edibles must also meet food law.

What is not required: a named accredited lab on the pack, terpene figures, or a public certificate of analysis. The trial and the canton hold the paperwork; you hold the label.

The part you can check yourself: the sealed, plain pack

In a trial, the pack is the proof. It must be sealed, child-resistant if it is eaten or drunk, and plain: a neutral product name, the weight, total THC and CBD in percent, the name of the trial, a health warning, a note on dependence, a warning about driving, a hint on lower-risk ways to use, and the notice that the product may not be passed on and not to anyone under 18. Advertising is banned. Zürich's Züri Can trial, for example, is building a range of 13 products, ten flowers and three hashes, between 5 and 20 percent THC, in 5-gram packs.

The trial also controls who buys. You must already use cannabis, live in the trial's canton, sign consent and hold a participant QR code that is scanned at every purchase (Basel also asks for your identity card). The limit is 10 grams of product per purchase and 10 grams of THC per month, every gram logged, and the price is set to track the local black market so the trial does not undercut it.

Outside a trial, a legal CBD product should show under 1 percent total THC, and for imports the importer must hold a batch-specific certificate of analysis from an ISO/IEC 17025 or GMP laboratory. Ask for it. There is no such duty for street cannabis, because there is no legal street cannabis.

The twist: the trials say it works, and Parliament sent the law back

The trials were built to answer one question: does regulated sale change how people use? The evidence so far says consumption does not rise. Basel's Weed Care found after three years that its health-oriented model reduced risks without increasing use. The Bern, Biel and Lucerne SCRIPT trial, with 1,177 participants in nine pharmacies, reported on 7 September 2026 that use trended slightly down and saw signs that some participants were switching from smoking to vaporising or oral products. The FOPH's own summary: access got easier, use did not increase.

Meanwhile the draft federal Cannabis Products Act, drawn up by the National Council's health committee, went out to consultation from 29 August to 1 December 2025. It would let residents grow three flowering plants, cap possession in public at 5 grams of total THC, sell only through a limited number of non-profit outlets plus one nationwide online seller, in plain packs with warnings, tracked from seed to sale and with a full advertising ban. The cantons split 10 for and 15 against. On 6 to 8 May 2026 the committee voted 16 to 8, with one abstention, to keep going, rejected waiting for the trial results, and sent the draft back to its subcommittee for a rewrite. Until that returns, the trials remain the only legal, tested cannabis for non-medical use in Switzerland.

What it means for you

In a pilot trial: read the total THC and CBD on the pack, remember the 25 percent tolerance, keep the pack sealed until you are home, and never pass it on. Your QR code is your access; the trial can exclude you for misuse.

Buying CBD: look for under 1 percent total THC, ignore any health claim (they are prohibited), and ask for the batch certificate of analysis. Smoking products should carry the tobacco-law warnings.

Medical patients: your pharmacy compounds from pharmacopoeia-grade flower under Swissmedic's system; ask the pharmacist about the batch. Budget for the cost, since insurance rarely pays.

Anywhere else: assume it is untested. A CHF 100 fine is the least of the risks; there is no lab, no cap and no recall behind a street bag. Home growing of THC cannabis remains a crime.

Questions people ask

Is cannabis legal in Switzerland? No. Cannabis with 1 percent THC or more is a narcotic; growing, producing and selling it are crimes, and consuming it costs an adult a CHF 100 fixed fine, with up to 10 grams treated as a minor quantity. Two exceptions exist: doctors have been able to prescribe medical cannabis without a federal exemption permit since August 2022, and eight federally authorised pilot trials may sell regulated cannabis to registered adult participants until 2031 at the latest.

Which Swiss cities have a legal cannabis pilot trial? Basel (Weed Care), Zürich (Züri Can, plus the canton's Cannabis Research Zürich in six municipalities), Geneva (La Cannabinothèque in Vernier), Lausanne (Cann-L), Liestal and Allschwil in Basel-Landschaft (Grashaus Projects), Bern, Biel and Lucerne (SCRIPT), and five towns in the canton of St. Gallen (CanLeg, from 2026). Together they run about 56 sales points: pharmacies, social clubs, a drug information centre and specialist shops, some non-profit and some commercial.

Is CBD legal in Switzerland? Yes, if the product contains less than 1 percent total THC. It is regulated as a food, cosmetic, tobacco product, chemical or medicine depending on how it is sold, health claims are not allowed, CBD flower and e-liquids can be sold as smoking products under the tobacco law since October 2024, and imported CBD needs a batch certificate of analysis from an accredited or GMP lab.

Want to see the whole chain, from licensed grower to sealed pack, step by step? Play the interactive walkthrough at weed-central.com/learn/coa/switzerland (https://weed-central.com/learn/coa/switzerland?utm_source=newsletter.weed-central.com&utm_medium=newsletter&utm_campaign=who-s-responsible-for-cannabis-safety-in-switzerland), and compare it with how other countries and US states do it at weed-central.com/learn/coa (https://weed-central.com/learn/coa?utm_source=newsletter.weed-central.com&utm_medium=newsletter&utm_campaign=who-s-responsible-for-cannabis-safety-in-switzerland).

This article is general information, not legal or medical advice. Swiss cannabis rules differ by canton and trial and can change; verify the current requirements before relying on any detail.